Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway

Sacubitril/valsartan (Sac/Val) is a recently approved drug that is commonly used for treatment of heart failure. Several studies indicated that Sac/Val also regulated the secretion of inflammatory factors. However, the effect and mechanism of this drug modulation of inflammatory immune responses are...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Wei, Xie, Bai-Kang, Ding, Pei-Wu, Wang, Min, Yuan, Jing, Cheng, Xiang, Liao, Yu-Hua, Yu, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479108/
https://www.ncbi.nlm.nih.gov/pubmed/34603042
http://dx.doi.org/10.3389/fphar.2021.727838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479108/
https://www.ncbi.nlm.nih.gov/pubmed/34603042
http://dx.doi.org/10.3389/fphar.2021.727838

Ejemplares similares